Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sino-Western rivalry in the COVID-19 “vaccine wars”–A race to the bottom?

Sino-Western rivalry in the COVID-19 “vaccine wars”–A race to the bottom? This paper analyses the escalating Sino-Western race to develop a safe, efficacious and durable vaccine (i.e. “Goldilocks COVID-19 vaccine”). It argues that such efforts would be considerably more effective if there is greater international cooperation instead of the corrosive rivalry driven by misplaced nationalism.Design/methodology/approachThis study deploys a case-study approach, supported by literature on existing coronavirus disease 2019 (COVID-19) vaccine development efforts.FindingsDespite the seeming success of recent COVID-19 vaccines, their actual efficacy is far from certain. Moreover, access to these vaccines would not be equitable internationally. This problem is exacerbated by the fact that their unique properties make storage and distribution prohibitively expensive, and international mechanisms to provide distribution to economically depressed regions are non-existent. Given the significant difficulties, it would be incumbent upon the great powers (i.e. China and America) to work together not only in vaccine development but also in the establishment of a distribution platform to ensure equitable access worldwide.Originality/valueThis study is one of the few social science research papers on COVID-19 vaccine development and its implications for society at large. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asian Education and Development Studies Emerald Publishing

Sino-Western rivalry in the COVID-19 “vaccine wars”–A race to the bottom?

Download PDF
13 pages

Loading next page...
 
/lp/emerald-publishing/sino-western-rivalry-in-the-covid-19-vaccine-wars-a-race-to-the-bottom-0C0GppvizC
Publisher
Emerald Publishing
Copyright
© Emerald Publishing Limited
ISSN
2046-3162
DOI
10.1108/aeds-12-2020-0271
Publisher site
See Article on Publisher Site

Abstract

This paper analyses the escalating Sino-Western race to develop a safe, efficacious and durable vaccine (i.e. “Goldilocks COVID-19 vaccine”). It argues that such efforts would be considerably more effective if there is greater international cooperation instead of the corrosive rivalry driven by misplaced nationalism.Design/methodology/approachThis study deploys a case-study approach, supported by literature on existing coronavirus disease 2019 (COVID-19) vaccine development efforts.FindingsDespite the seeming success of recent COVID-19 vaccines, their actual efficacy is far from certain. Moreover, access to these vaccines would not be equitable internationally. This problem is exacerbated by the fact that their unique properties make storage and distribution prohibitively expensive, and international mechanisms to provide distribution to economically depressed regions are non-existent. Given the significant difficulties, it would be incumbent upon the great powers (i.e. China and America) to work together not only in vaccine development but also in the establishment of a distribution platform to ensure equitable access worldwide.Originality/valueThis study is one of the few social science research papers on COVID-19 vaccine development and its implications for society at large.

Journal

Asian Education and Development Studies – Emerald Publishing

Published: Sep 9, 2021

Keywords: Global public goods; Goldilocks COVID-19 vaccine; Kicking away the ladder; Vaccine nationalism; Vaccine race

References

  • Opinion: Pfizer vaccine refutes Trump's nationalism, attacks on science
    Asaravala, C.
  • The false promise of herd immunity for COVID-19
    Aschwanden, C.
  • COVID-19 vaccine AZD1222 clinical trials resumed in the UK
  • Coronavirus: US buys nearly all of Gilead's Covid-19 drug remdesivir
  • China under pressure to reveal vaccine data after pfizer success
  • US purchases world stocks of Remdesivir—why the rest of the world should be glad to be at the back of the queue
    Brophy, J.M.
  • What Pfizer's landmark COVID vaccine results mean for the pandemic
    Callaway, E.
  • Why Oxford's positive COVID vaccine results are puzzling scientists
    Callaway, E.
  • Russia's fast-track coronavirus vaccine draws outrage over safety
    Callaway, E.
  • Trump's going all in on a vaccine. He may still get beaten by China
    Champion, M.
  • Contribution of NIH funding to new drugapprovals 2010–2016
    Cleary, E.G.; Beierlein, J.M.; Khanuja, N.S.; McNamee, L.M.; Ledley, F.D.
  • The secret group of scientists and billionaires pushing a manhattan Project for covid-19
    Copeland, T.
  • Immune status could determine efficacy of COVID-19 therapies
    Cully, M.
  • What China's speedy COVID vaccine deployment means for the pandemic
    Cyranoski, D.
  • Presidential debate: donald trump blames ‘China plague’ for US economic woes
    Delaney, R.
  • In blow to Fosun pharma, its German partner to make covid-19 vaccine for China market
    Di, N.; Murphy, F.
  • Experimental covid-19 vaccines given to hundreds of thousands of Chinese
    Di, N.; Tang, H.Y.; Jia, T.Q.; Jia, D.
  • Intent to get a COVID-19 vaccine rises to 60% as confidence in research and development process increases
    Funk, C.; Tyson, A.
  • Covid-19: Oxford University vaccine is highly effective
    Gallagher, J.
  • Track on COVID-19 vaccines: China has 11 vaccines in clinical trials, four in phase III
    Gao, Y.
  • America needs to win the coronavirus vaccine race
    Gottlieb, S.
  • What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?
    Hellerstein, D.
  • What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
    Hodgson, S.H.; Mansatta, K.; Mallett, G.; Harris, V.; Emary, K.R.W.; Pollard, A.J.
  • Mistrust of a coronavirus vaccine could imperil widespread immunity
    Hoffman, J.
  • 3rd major COVID-19 vaccine shown to be effective and cheaper
    Kirka, D.
  • There's a new Trump administration coronavirus outbreak
    Klein, C.
  • BioNTech gets $445 million in German funding for vaccine
    Kresge, N.
  • New coronavirus variants could cause more reinfections, require updated vaccines
    Kupferschmidt, K.
  • Opinion: scientists in the US and China collaborating on COVID-19
    Lee, J.J.; Haupt, J.P.
  • The 5 stages of COVID-19 vaccine development: what you need to know about how a clinical trial works
    Levine, H.
  • CIA attacks Chinese web firms, organs for a decade
    Liu, C.Y.
  • Coronavirus: China approves clinical trial for German vaccine candidate
    McCarthy, S.
  • America First and the human rights regime
    Mills, K.; Payne, R.A.
  • Moderna's work on a COVID-19 vaccine candidate
  • Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study
  • COVID vaccine confidence requires radical transparency
  • Pfizer slashed its original covid-19 vaccine rollout target after supply-chain obstacles
    Paris, C.
  • The great vaccine race: inside the unprecedented scramble to immunize the world against COVID-19
    Park, A.
  • Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of MRNA-based vaccine candidate against SARS-COV-2
  • Pfizer and BioNTech announce Vaccine Candidate against COVID-19 achieved success in first interim analysis from Phase 3 Study
  • Pfizer and BioNTech conclude Phase 3 Study of COVID-19 Vaccine Candidate, meeting all primary efficacy endpoints
  • Fosun pharma gearing up to bring mRNA COVID-19 vaccine to China
  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
    Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; the Oxford COVID Vaccine Trial Group
  • Vaccine nationalism: the ugly face of science and politics
    Ramscar, H.
  • Oxford/AstraZeneca Covid vaccine ‘dose error’ explained
    Roberts, M.
  • Evaluating and deploying covid-19 vaccines — the importance of transparency, scientific integrity, and public trust
    Schwartz, J.L.
  • Expert reaction: Pfizer announces COVID-19 vaccine is 90% effective
  • Brazil regulator under fire after halting China-developed Covid vaccine trail
    Sheperd, C.; Harris, B.
  • Why does pfizer's COVID-19 vaccine need to Be kept Colderthan antarctica?
    Simmons-Duffin, S.
  • The first interim date analysis of the Sputnik V vaccine against COVID-19 phase III clinical trials in the Russian federation demonstrated 92% efficacy
    Sputnik, V.
  • The Cost of the Sputnik V Vaccine will be less than $10 for international markets
    Sputnik, V.
  • Super-spreaders in infectious diseases
    Stein, R.A.
  • African nations ‘far from ready’ for COVID-19 vaccination drive, says UN health agency
  • Fact sheet: explaining Operation Warp Speed
  • Two Chinese hackers working with the Ministry of state security charged with global computer intrusion campaign targeting intellectual property and confidential business information, including COVID-19 research
  • Development and licensure of vaccines to prevent COVID-19: guidance for industry
  • From asia to Africa, China promotes its vaccines to win friends
    Wee, S.L.
  • Chinese vaccine would be ‘global public good,’ Xi says
    Wheaton, S.
  • WHO director-general's opening remarks at the world health summit - 25 October 2020
  • China's AI strike force on COVID-19”
    Wong, W.K.O.
  • Four Chinese COVID-19 vaccines undergoing phase-3 clinical trials
  • Update: China's COVID-19 vaccine capacity to reach 610 million
  • Commentary: China develops COVID-19 vaccines as global public good